By Fineline Cube 
On August 22, 2025, China-based Lifetech Scientific Corporation (HKG: 1302) announced that its nitinol patent ductus arteriosus (PDA) occluder has been approved for the National Medical Products Administration’s (NMPA) special review procedure for innovative medical devices, marking the 16th product from the company to receive this status.
Product Innovation
Designed for the interventional treatment of congenital heart PDA, this occluder stands out as the first domestically developed PDA occluder with a full nitinol body. It allows for both “venous antegrade” and “arterial retrograde” release paths, offering new therapeutic options for patients with congenital heart defects.-Fineline Info & Tech